Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes
Harpinder Kaur, Nishant Shekhar, Saurabh Sharma, et al.
Pharmacological Reports (2021) Vol. 73, Iss. 3, pp. 736-749
Open Access | Times Cited: 87

Showing 1-25 of 87 citing articles:

Identification of novel inhibitors for SARS-CoV-2 as therapeutic options using machine learning-based virtual screening, molecular docking and MD simulation
Abdus Samad, Amar Ajmal, Arif Mahmood, et al.
Frontiers in Molecular Biosciences (2023) Vol. 10
Open Access | Times Cited: 51
In Vitro and In Vivo Models for Studying SARS-CoV-2, the Etiological Agent Responsible for COVID-19 Pandemic
Rafael Borges Rosa, Willyenne Marília Dantas, Jéssica Catarine Frutuoso do Nascimento, et al.
Viruses (2021) Vol. 13, Iss. 3, pp. 379-379
Open Access | Times Cited: 71
Therapeutics for COVID-19 and post COVID-19 complications: An update
Debdoot Basu, Vivek P. Chavda, Anita A. Mehta
Current Research in Pharmacology and Drug Discovery (2022) Vol. 3, pp. 100086-100086
Open Access | Times Cited: 69
The antiviral activity of iota-, kappa-, and lambda-carrageenan against COVID-19: A critical review
Andri Frediansyah
Clinical Epidemiology and Global Health (2021) Vol. 12, pp. 100826-100826
Open Access | Times Cited: 65
Developing a multiepitope vaccine for the prevention of SARS-CoV-2 and monkeypox virus co-infection: A reverse vaccinology analysis
Fan Jiang, Yinping Liu, Yong Xue, et al.
International Immunopharmacology (2023) Vol. 115, pp. 109728-109728
Open Access | Times Cited: 28
Attenuation of clinical and immunological outcomes during SARS‐CoV‐2 infection by ivermectin
Guilherme Dias de Melo, Françoise Lazarini, Florence Larrous, et al.
EMBO Molecular Medicine (2021) Vol. 13, Iss. 8
Open Access | Times Cited: 49
Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects
Slobodan Rendić
Archives of Toxicology (2021) Vol. 95, Iss. 5, pp. 1535-1546
Open Access | Times Cited: 47
COVID-19–Associated Rhino-Orbital-Cerebral Mucormycosis
Anusuya Bhattacharyya, Phulen Sarma, Hardeep Kaur, et al.
Indian Journal of Pharmacology (2021) Vol. 53, Iss. 6, pp. 499-510
Open Access | Times Cited: 46
Use of Antimicrobials among Suspected COVID-19 Patients at Selected Hospitals, Bangladesh: Findings from the First Wave of COVID-19 Pandemic
Syeda Mah‐E‐Muneer, Md Zakiul Hassan, Md Abdullah Al Jubayer Biswas, et al.
Antibiotics (2021) Vol. 10, Iss. 6, pp. 738-738
Open Access | Times Cited: 43
Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication
Zheng Yao Low, Ashley Jia Wen Yip, Sunil K. Lal
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2021) Vol. 1868, Iss. 2, pp. 166294-166294
Open Access | Times Cited: 42
Efficacy of Ivermectin, Chloroquine/Hydroxychloroquine, and Azithromycin in Managing COVID-19: A Systematic Review of Phase III Clinical Trials
Nathália Mariana Santos Sansone, Matheus Negri Boschiero, Fernando Augusto Lima Marson
Biomedicines (2024) Vol. 12, Iss. 10, pp. 2206-2206
Open Access | Times Cited: 8
RETRACTED: Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon
Ali Samaha, Hussein Mouawia, Mirna Fawaz, et al.
Viruses (2021) Vol. 13, Iss. 6, pp. 989-989
Open Access | Times Cited: 37
Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities
Zena Wehbe, Maya Wehbe, Rabah Iratni, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 36
Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors “leflunomide” and “teriflunomide” in Covid-19: A narrative review
Hardeep Kaur, Phulen Sarma, Anusuya Bhattacharyya, et al.
European Journal of Pharmacology (2021) Vol. 906, pp. 174233-174233
Open Access | Times Cited: 36
Heterocyclic compounds as antiviral drugs: Synthesis, structure–activity relationship and traditional applications
Giovanny Carvalho dos Santos, Lucas Michelão Martins, Bruna Andressa Bregadiolli, et al.
Journal of Heterocyclic Chemistry (2021) Vol. 58, Iss. 12, pp. 2226-2260
Closed Access | Times Cited: 36
Viewing SARS-CoV-2 Nucleocapsid Protein in Terms of Molecular Flexibility
Tatsuhito Matsuo
Biology (2021) Vol. 10, Iss. 6, pp. 454-454
Open Access | Times Cited: 34
A Deadly Embrace: Hemagglutination Mediated by SARS-CoV-2 Spike Protein at Its 22 N-Glycosylation Sites, Red Blood Cell Surface Sialoglycoproteins, and Antibody
David Scheim
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 5, pp. 2558-2558
Open Access | Times Cited: 26
Red blood cell-hitchhiking mediated pulmonary delivery of ivermectin: Effects of nanoparticle properties
Jinpeng Zheng, Caihong Lu, Yaning Ding, et al.
International Journal of Pharmaceutics (2022) Vol. 619, pp. 121719-121719
Open Access | Times Cited: 26
Ivermectin for Prophylaxis and Treatment of COVID-19: A Systematic Review and Meta-Analysis
Mario Cruciani, Ilaria Pati, Francesca Masiello, et al.
Diagnostics (2021) Vol. 11, Iss. 9, pp. 1645-1645
Open Access | Times Cited: 32
Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching
Lucy Kerr, Flavio Cadegiani, Fernando Baldi, et al.
Cureus (2022)
Open Access | Times Cited: 19
Sialylated Glycan Bindings from SARS-CoV-2 Spike Protein to Blood and Endothelial Cells Govern the Severe Morbidities of COVID-19
David Scheim, Paola Vottero, Alessandro D. Santin, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 23, pp. 17039-17039
Open Access | Times Cited: 12
Ivermectin as a Potential Addition to the Limited Anti-COVID-19 Arsenal: A Double-Blinded Clinical Trial
Mehran Varnaseri, Fatemeh Amini, Ramin Jamshididan, et al.
Jundishapur journal of health sciences (2024) Vol. 16, Iss. 2
Open Access | Times Cited: 4
Ivermectin as a Treatment Modality in COVID-19 Patients: A Systematic Review and Meta-Analysis of Up-To-Date RCTs
Raghava Kalyan Maddukuri, Madhavi Latha Desimalla, Reshma Banavathu, et al.
Indian Journal of Community Medicine (2025) Vol. 50, Iss. 1, pp. 9-19
Open Access
Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions
Subrata Deb, Anthony Allen Reeves
Journal of Pharmacy & Pharmaceutical Sciences (2021) Vol. 24, pp. 277-291
Open Access | Times Cited: 26
Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials
Qinglin Cheng, Chen Jun-fang, Qingjun Jia, et al.
Aging (2021) Vol. 13, Iss. 18, pp. 21866-21902
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top